Moderna picks its moment
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Convatec has a poor third quarter for the second year running
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Abivax seeks funds to follow another fork
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
Could big biotech succumb to the urge to merge?
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.